TMC Pharma Services

COVID-19 (Coronavirus) Notice


In light of the current global Coronavirus-related situation, we want to reassure you that TMC is working hard to ensure all controllable aspects of our services continue as normally as possible, and that any disruptions caused by restrictions in travel etc. are minimised as much as possible. Supporting our ongoing projects is obviously key and we will continue to manage and monitor our projects and liaise with you as needed.


At TMC, we are of course monitoring daily the available global and local advice on precautions necessary to curtail the spread of Covid-19, and we are taking appropriate measures to manage the continually-changing situation.


We have a robust Business Continuity Plan (BCP), which allows all of our team to work remotely should the need arise. We have recently reviewed our BCP in the light of this extraordinary situation to ensure all business critical functions will continue if our employees have to self-isolate.

A Unique Global Pharmaceutical Development Organisation Providing a Full Range of Expert Pharma/Biotech Support Services

TMC is unique in two ways:

Firstly

The breadth of our services...

We offer end-to-end services, from pre-clinical to post-marketing, Pharma/Biotech development services for human & veterinary medicines and devices.

Secondly

The way we provide those services...

We tailor our range of services to every Client’s individual needs and our worldwide team of over 600 mature experts can be used to manage as much, or as little, as a client company needs.

What We Do


Our development support activities span early pre-clinical phase right through to post-marketing. TMC provides all the functions of a fully-resourced pharmaceutical company and we often provide 'bolt-on' services complementing a client's in-house resource to enable them to have all the development capability appropriate to the stage of their project.

We cover all therapeutic areas but have particular expertise in:

  • Rare and orphan diseases
  • Advanced Therapy Investigational Medicinal Products including stem cells and other cell-based therapies
  • Oncology including biologics and immuno-oncology

We have pioneered the early development pathway for novel advanced therapy agents; right from the manufacturing stage.

How We Do It


The TMC network of over 600 personnel (Employees and Associates) includes some of the very best subject-matter experts in medicinal product development.

Our specific teams are hand-picked to match exactly the needs of each individual project, they evolve smoothly along with the progress of the project, responding intelligently to the specific needs at each stage of development, driving the project to a successful conclusion.

This approach makes us nimble, light on our feet, flexible and cost-effective.

Where We Do It


TMC is working all over the Globe. We have offices and hubs in key countries – particularly in EU, UK, Japan and North America.

Our core team of highly-experienced Senior Executives in TMC's Head Office collaborate with our loyal and established network of Associates located around the world.

We are continuously adding Associates to the team, as required, and they all provide expert, current, local knowledge.

Our Clients

TMC works right across the size spectrum of pharma/biotech companies worldwide (from start-ups to Big Pharma) and Academic Institutions.

Partnership: The TMC Way Of Working

TMC came from a consultancy background. This makes us different from other service providers: we prefer to act as partners with our clients, providing a blend of consultancy/strategic advice and efficient implementation.

Our highly experienced team has an outstanding track record of delivering successful projects across the following disciplines: